A monoclonal antibody, designated A2a1 8b8, of IgGi class prepared against human a1-antitrypsin, cross-reacts with a1-antitrypsin in the serum of rat and baboon, but not with 
Inflammation
in mammals caused by chemical agents and pathological conditions such as bacterial infection, major surgery, or burns elicits an increase in the concentration in serum of some glycoproteins collectively referred to as "acute-phase proteins" (1). Several of such proteins have been isolated and characterized, including a-and a-globulins (such as a1-acid glycoprotein, fibrinogen, and ceruloplasmin), proteinase inhibitors (a1-antitrypsin, a1-antichymotrypsin, and a2-macroglobulin), C-reactive protein, amyloid A-related protein, and amyloid P-componentrelated protein (for a review, see 2). It has been suggested that some of these acute-phase proteins might arise as a result of protein denaturation, with formation of new epitopes (3).
Although the physiological consequences of the increases of these proteins, if any, in the inflammatory responses are not well understood, these proteins must play a unique biological role in the acute responses because they are highly conserved throughout evolution, and normal concentrations are maintained even during severe malnutrition (2). Assay of these acute-phase proteins for diagnosis has been limited, because their concentrations increase uniformly in all inflammatory disorders, regardless of the cause. Here we present evidence indicating that a monoclonal antibody prepared against a specific epitope(s) of a1-antitrypsun can be of diagnostic value for certain inflammatory disorders.
Materials and Methods

Biochemicals
Ths, acrylamide, N,N'-diallyltartardiamide, N,N'-methylenebis(acrylamide), N,N,N',N'-tetramethylethylenediamine, animonium persulfate, prestained high-molecular- Production of ascitic fluid. Positive hybridoma cells were cloned by limiting dilutions. Selected clones were expanded in vivo by intraperitoneal injection of 3 x 106 hybridoma cells per mouse into syngeneic mice. Each mouse was primed with 0.5 mL of pristane at least seven days before its use for ascitic fluid production.
Ascitic fluid was collected from the tumors 10 to 20 days after injection of hybridoma cells. The ascitic fluid was centrifuged at 2500 x g for 10 mm at 4 #{176}C to remove debris, and the supernate was stored at -20 #{176}C until used.
Enzyme-linked immunoassay for a1 -antitrypsin. If this radioimmunoassay is assumed to measure all of the a1-antitrypsin macromolecules in the biological samples, then the monoclonal antibody used for the ELISA is recognizing a specific epitope on the a1-antitrypsin that is present on only 19% of those macromolecules.
We computer-analyzed all data derived from radioimmunoassay and ELISA by fitting standard curves to a four-parameter logistic function and interpolating unknowns from the resulting curves, using a computer program (26).
NH2-terminal sequence analysis. To determine the Nterminal amino acid sequence of a1-antitrypsin, we used a Model 470A gas-phase analyzer (Applied Biosystems, Foster City, CA) with 0.1 nmol of native a1-antitrypsin, as detailed elsewhere (27, 28) .
Results
Purification of a1 -antitrypsin.
a1-Antitrypsin was purified to apparent homogeneity by using sequential Con A-Sepharose chromatography, and by anion-exchange, gel permeation, hydroxylapatite, and reversed-phase HPLC, with an overall recovery of about 10% of the starting material.
We routinely recovered 10 mg of purified a1-antitrypsin from a 20-mL batch of human serum. Purified a1-antitrypsin eluted from a Vydac C18 reversed-phase HPLC column (Figure l#{192} (Figure 18, lane 3) . When this preparation was labeled with Jodogen and fractionated by SDS-PAGE, only one radioactive band was detected, which corresponded to the Coomassie-Blue-stained portion of the gel (cf. Figure 1C, 18) . These analyses unequivocally demonstrated the purity of a1-antitrypsin.
NH2-terminal sequence analysis. To verify that the isolated protein from human sera was indeed a1-antitrypsin, we determined its NH2-terminal amino acid sequence by using a gas-phase sequenator. 
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antibody (A2a18b8), directed against a specific epithpe of a1-antitrypsin, was selected for subsequent studies. Ascitic fluid was produced by injecting into pristane-primed mice the hybridoma cells secreting A2a18b8 monoclonal antibodies. As determined by radial immunodiffusion, A2a18b8 belonged to the IgGl subclass (Figure 2A) . The monospecificity of this monoclonal antibody was further demonstrated by immunoblots with two-dimensional gels, in which crude human serum was fractionated by two-dimensional gel electrophoresis; a1-antitrypsin appeared as a single band, with p1 between 4.85 and 4.95 (Figure 28 ).
When we used A2a18b8 to screen by immunostaining samples obtained from patients with inflammatory disorders, this monoclonal antibody interacted differently with samples obtained from normal individuals and with samples from patients with various inflammatory disorders ( Figure 3 ). This suggests that this monoclonai antibody might be clinically valuable for screening serum samples to define various classes of inflammatory disorders. we noted that A2a18b8 monoclonal antibody cross-reacted with a macromolecule present in the serum of several species, including rat and baboon; however, it did not cross-react with proteins in the serum of hamster, turtle, dog, or chicken (data not shown). Figure 5 illustrates results by the ELISA for a1-antitrypsin in the 247 serum samples from patients with SLE, MCTD, RA, SCL, SJO, and normal donors. Of particular interest is the finding that the concentration of a specific epitope(s) of a1-antitrypsin was significantly greater in patients with SLE, MCTD, and RA than in the normal donors. it seems logical to speculate that this monoclonal antibody is directed against a specific conformation of a1-antitrypsin at the site of glycosylation or at the carbohydrate moiety of a specific variant that has been altered during inflammation. The preliminary screening of serum samples from patients with various inflammatory disorders and normal donors has indicated that the antigen reacting with this monoclonal antibody increases selectively in patients with active SLE, MCTD, and RA, but not with SCL and SJO. Thus, it will be of interest to define the structure of the antigenic domain being recognized by this monoclonal antibody.
DIscussion
a1-Antitrypsin, a protease inhibitor, shares 30%, 29%, and 23% sequence homology with ovalbuinin (36), antithrombin-Ul (33), and angiotensinogen (37), respectively, which are functionally unrelated polypeptides. Recent studies comparing the cDNAs coding for a1-antitrypsin, haptoglobin, and a1-acid glycoprotein have shown that their cDNAs all possess a conserved sequence within the 5'-untranslated region. This region may thus play a role during an acute-phase response (38) . Among all the existing diagnostic assays available for screening inflammatory and autoimxnune diseases, more than 90% of the screening effort is directed towards the detection of antibodies against DNA and nuclear protein and of the Fc fragments of the IgG molecules (rheumatoid factors). The disadvantages of these existing techniques include their inability to distinguish the severity of the illness and to guide prognosis of treatment.
The possible diagnostic value of the monoclonal antibody prepared against a1-antitrypsin in distinguishing various inflamniatory disorders may be considerable.
In conclusion, we have prepared a monoclonal antibody against a1-antitrypsin and have developed a specific EUSA for use with this antibody. Preliminary screenings indicate that it will be a useful marker to study the etiology of active SLE, RA, and MCTD. Work is now in progress to investigate whether this assay can be used to follow the effects of treatment among patients with SLE, MCTD, and RA.
